Rare and Orphan Disease Companies
Comprehensive directory of biotechnology and pharmaceutical firms developing life-changing therapies for rare and orphan diseases with high unmet medical needs.
Navigating Rare and Orphan Disease Companies requires a specialized focus on clinical milestones, FDA exclusivity windows, and breakthrough modalities like gene therapy and RNAi. As of 2026, the sector is defined by high-margin orphan drugs that benefit from seven years of market exclusivity and significant tax credits. Investors often use a compare rare disease metrics tool to track binary Phase 3 catalysts that can drive massive valuation shifts. Whether monitoring established leaders or emerging biotech overview pipelines, understanding the unique economics of orphan designations is key. This directory provides a centralized view of the U.S.-listed firms pioneering treatments for patient populations under 200,000.
Key Takeaways
Orphan Drug Designation grants firms 7 years of market exclusivity and 50% tax credits on clinical trials, leading to gross margins near 80% for leaders like the BioMarin profile.
Stock performance is heavily driven by binary Phase 3 data readouts and FDA PDUFA dates, which can lead to 200%+ upside for successful orphan indications.
Single-dose cures for diseases like DMD or Pompe are reaching the market in 2026, commanded by firms such as the Sarepta DMD pipeline.
Rare disease assets are primary targets for Big Pharma, with acquisition premiums averaging 60% as majors look to replace looming patent cliffs.
Top Rare and Orphan Disease Companies by Market Cap (2026)
The following table ranks the leading rare disease specialists and large-cap biopharmas with dominant orphan drug portfolios by early 2026 valuation.
| Rank | Ticker | Company | Industry | Market Cap | YTD % | Lead Indication | Phase |
|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc. | Biotechnology | $173B | +18% | ALS (Horizen) | Phase 3 |
| 2 | GILD | Gilead Sciences | Biotechnology | $150B | +31% | Orphan HIV | Marketed |
| 3 | VRTX | Vertex Pharma | Biotechnology | $113B | +5% | Cystic Fibrosis | Marketed |
| 4 | ALNY | Alnylam Pharma | Biotechnology | $57B | +72% | ATTR Amyloidosis | Phase 3 |
| 5 | BMRN | BioMarin Pharma | Biotechnology | $15B | +2% | Achondroplasia | Marketed |
| 6 | SRPT | Sarepta Therapeutics | Biotechnology | $12B | +14% | Duchenne MD | Phase 3 |
| 7 | VKTX | Viking Therapeutics | Biotechnology | $8.5B | +210% | Rare Liver Disease | Phase 3 |
| 8 | KRYS | Krystal Biotech | Biotechnology | $4.2B | +45% | Dystrophic EB | Marketed |
| 9 | RARE | Ultragenyx Pharma | Biotechnology | $3.8B | +8% | Pompe Disease | Phase 3 |
| 10 | BLUE | bluebird bio | Biotechnology | $0.4B | -12% | Sickle Cell | Marketed |
Rare and Orphan Disease Companies — Complete Company List
List of Publicly Traded Companies Focusing on Rare Diseases Listed on U.S. Exchanges
Rare Diseases: Large-Cap Stocks
- Alexion Pharmaceuticals, Inc. (ALXN) (Biopharmaceutical company: nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, hypophosphatasia, Lysosomal Acid Lipase Deficiency)
- BioMarin Pharmaceutical Inc. (BMRN) (Therapies for serious and life-threatening rare and ultra-rare genetic diseases)
Rare Diseases: Mid-Cap Stocks
- Horizon Pharma plc (HZNP) (Ireland, biopharmaceutical company: arthritis pain, rare diseases)
- Intercept Pharmaceuticals, Inc. (ICPT) (Biopharmaceutical company: orphan and more prevalent liver diseases)
- Ionis Pharmaceuticals, Inc. (IONS) (RNA-targeted drug discovery and development: cancer, cardiovascular, metabolic, neurological disorders, rare diseases)
- Sarepta Therapeutics, Inc. (SRPT) (Biopharmaceutical company: RNA-based therapeutics; rare and infectious diseases)
- Ultragenyx Pharmaceutical Inc. (RARE) (Biopharmaceutical company: debilitating genetic diseases)
Rare Diseases: Small-Cap Stocks
- Acceleron Pharma Inc. (XLRN) (Cancer and orphan diseases)
- Agios Pharmaceuticals, Inc. (AGIO) (Biopharmaceutical company: cancer and rare genetic disorders of metabolism)
- Amicus Therapeutics, Inc. (FOLD) (Biopharmaceutical company: lysosomal storage diseases)
- Audentes Therapeutics, Inc. (BOLD) (IPO July 20, 2016: biotech company focused on therapy treatments for rare diseases)
- Avexis Inc. (AVXS) (IPO February 11, 2016: Gene therapy company with a focus on rare neurological genetic diseases)
- Bluebird Bio, Inc. (BLUE) (Gene therapies for severe genetic and rare diseases)
- Insmed, Inc. (INSM) (Biopharmaceutical company: lung disease and pulmonary arterial hypertension)
- Raptor Pharmaceutical Corp. (RPTP) (Biopharmaceutical company: nephropathic cystinosis)
- Spark Therapeutics, Inc. (ONCE) (Gene therapies: treatments for debilitating genetic diseases)
Rare Diseases: Micro-Cap Stocks
- Abeona Therapeutics (ABEO) (Gene therapy and plasma-based products)
- Adverum Biotechnologies, Inc. (ADVM) (Biopharmaceutical company: serious eye diseases)
- Aegerion Pharmaceuticals, Inc. (AEGR) (Biopharmaceutical company: homozygous familial hypercholesterolemia)
- Akari Therapeutics, Plc (AKTX) (United Kingdom, biopharmaceutical company: therapeutics to treat orphan autoimmune and inflammatory diseases)
- aTyr Pharma Inc. (LIFE) (IPO in MAY 2015: Medicines used in the treatment of severe rare diseases)
- Catabasis Pharmaceuticals Inc. (CATB) (Biopharmaceutical company: rare diseases, serious lipid disorders)
- Catalyst Pharmaceuticals, Inc. (CPRX) (Biopharmaceutical company: rare neuromuscular and neurological diseases)
- Chiasma Inc. (CHMA) (IPO in July 2015, biopharmaceutical company: oral versions of injected drugs for orphan diseases)
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) (Biopharmaceutical company: rare, life-threatening, inflammatory diseases)
- Dimension Therapeutics Inc. (DMTX) (IPO in October 2015: Gene therapy platform company: rare diseases associated with the liver)
- Fate Therapeutics, Inc. (FATE) (Biopharmaceutical company: cellular immunotherapeutics; cancer, rare genetic diseases and immune disorders)
- Idera Pharmaceuticals, Inc. (IDRA) (B-cell Lymphoma, autoimmune, rare diseases)
- Medgenics, Inc. (MDGN) (Ex vivo gene therapy platform)
- MyoKardia Inc. (MYOK) (IPO in October 2015: Biopharmaceutical company; therapies for serious and neglected rare cardiovascular diseases)
- PTC Therapeutics, Inc. (PTCT) (Biopharmaceutical company: oral treatments)
- Strongbridge Biopharma plc (SBBP) (IPO in October 2015: Biopharmaceutical company; rare endocrine disorders and other rare diseases)
- Summit Therapeutics Plc. (SMMT) (IPO in March 2015: United Kingdom, biopharmaceutical company: Duchenne Muscular Dystrophy, infectious disease caused by the bacteria C. difficile)
- UniQure N.V. (QURE) (Netherlands: gene therapy)
- Xenon Pharmaceuticals Inc. (XENE) (Canada, biopharmaceutical company: lipoprotein lipase deficiency)
Rare Diseases: Nano-Cap Stocks
- Bio Blast Pharma Ltd. (ORPN) (Israel: therapies for patients with rare and ultra-rare genetic diseases)
- Eiger BioPharmaceuticals, Inc. (EIGR) (Biopharmaceutical company: Hepatitis Delta, Hypoglycemia, Pulmonary Arterial Hypertension, Lymphedema)
- Phaserx, Inc. (PZRX) (IPO May, 18 2016: biopharmaceutical company focused on treatments for enzyme deficiencies in the liver)
Risks & Considerations
Clinical Trial Binary Risk
Small-cap biotechs often rely on a single lead asset. Failure to meet primary endpoints in a Phase 3 trial can result in an immediate 70-90% loss of market value.
Payer and Reimbursement Barriers
Gene therapies often carry price tags exceeding $2 million. High costs can lead to intense negotiations with insurance providers, delaying commercial uptake and revenue growth.
Regulatory Shift Sensitivity
Accelerated approval pathways are critical for rare diseases but can be revoked if post-marketing trials fail to confirm clinical benefit, leading to product withdrawals.
Low Patient Prevalence
Identifying and enrolling patients for clinical trials in ultra-rare indications can lead to multi-year enrollment delays, increasing cash burn and extending development timelines.